At a glance
| Known as | ORX142 |
|---|---|
| Sponsor | Centessa Pharmaceuticals — a wholly owned subsidiary of Eli Lilly since 24 Jun 2026 |
| Mechanism | Orexin receptor agonist |
| Stage | Phase 1 |
| Indications | Neurological · Neurodegenerative |
| Registered trials | 1 · 1 recruiting |
| Last verified | 4 Aug 2026 |
Where it stands
ORX142 is where this class starts to point somewhere other than narcolepsy. Centessa, now owned by Eli Lilly, describes it as targeting select neurological and neurodegenerative disorders rather than sleep disorders specifically.
The Phase 1 study is recruiting healthy adults and older adults and includes a sleep-deprivation proof-of-concept arm. Enrolling older adults at Phase 1, rather than the usual young healthy volunteers, is consistent with a compound intended for conditions of ageing.
Registered trials
All 1 study on ClinicalTrials.gov that name ORX142 or its development code, pulled from the registry on 4 Aug 2026.
| Registry ID | Study | Phase | Status | Primary completion |
|---|---|---|---|---|
NCT07082829 |
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of AgeHealthy adults and older adults, including a sleep-deprivation proof-of-concept arm. Recruiting.208 participants | Phase 1 | Recruiting | 15 Jun 2026 |
Trial records are maintained by the sponsor and change without notice. Follow each link for current recruitment status and eligibility.
ORX142 — common questions
What is ORX142 for?
Centessa describes it as targeting select neurological and neurodegenerative disorders, not narcolepsy specifically. Its Phase 1 study includes a sleep-deprivation proof-of-concept arm.
What phase is ORX142 in?
Phase 1. Study NCT07082829 is recruiting healthy adults and older adults.
Source
This entry was last checked against its primary source on 4 Aug 2026: https://clinicaltrials.gov/study/NCT07082829
Found something out of date? Send a correction with a primary source and it will be fixed.
Get told when this changes
One email when ORX142 changes phase, reads out, or hits a regulatory milestone.
One email per real change. No tracking pixels, no list rental, one-click unsubscribe.